Zobrazeno 1 - 10
of 575
pro vyhledávání: '"D. H. Schwartz"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jacques, Louis1,2 (AUTHOR) louis.jacques.med@ssss.gouv.qc.ca
Publikováno v:
Brain Sciences (2076-3425). Dec2024, Vol. 14 Issue 12, p1261. 26p.
Autor:
M. Holodniy, D. A. Katzenstein, S. Sengupta, A. M. Wang, C. Casipit, D. H. Schwartz, M. Konrad, E. Groves, T. C. Merigan
Publikováno v:
Journal of Infectious Diseases. 190:2050-2054
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e86c46873e1bd4dce47ffff79835071b
https://doi.org/10.1086/190.11.2050
https://doi.org/10.1086/190.11.2050
Autor:
S H Pincus, K G Messer, R Cole, R Ireland, T C VanCott, A Pinter, D H Schwartz, B S Graham, G J Gorse
Publikováno v:
The Journal of Immunology. 158:3511-3520
The first generation of candidate vaccines to prevent HIV infection consisted of recombinant envelope proteins (Env, gp120, and gp160) derived from a single laboratory strain of HIV, designated IIIB/LAV, but produced with different expression systems
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04313bbd06711a7259a388c1a659bcea
https://doi.org/10.4049/jimmunol.158.7.3511
https://doi.org/10.4049/jimmunol.158.7.3511
Autor:
Chebaibi, Mohamed1 mohamed.chebaibi@usmba.ac.ma, Bourhia, Mohammed2, ez-zahra Amrati, Fatima3, Slighoua, Meryem3, Mssillou, Ibrahim4, Aboul-Soud, Mourad A. M.5, Khalid, Asaad6 akahmed@jazanu.edu.sa, Hassani, Rym7, Bousta, Dalila8, Achour, Sanae9, Benhida, Rachid10, Daoud, Rachid10 rachid.daoud@um6p.ma, Sudarshan, Kasireddy11, Aggarwal, Navidha12
Publikováno v:
Frontiers in Chemistry. 2024, p01-15. 15p.
Publikováno v:
Journal of Clinical Investigation. 92:840-847
Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers Squibb, Seattle, WA) and boosted with baculovirus-derived rgp160 (VaxSyn; MicroGeneSys, Inc., Meriden, CT) were evaluated for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a850e63fa94b70cd4e2825685d07b2df
https://doi.org/10.1172/jci116658
https://doi.org/10.1172/jci116658
Autor:
Murphy DH; University of California Los Angeles, Los Angeles, CA, USA. Dillon.Murphy@asu.edu.; Department of Psychology, Arizona State University, Tempe, AZ, USA. Dillon.Murphy@asu.edu.; University of California, Riverside, CA, USA. Dillon.Murphy@asu.edu.
Publikováno v:
Psychonomic bulletin & review [Psychon Bull Rev] 2024 Aug 13. Date of Electronic Publication: 2024 Aug 13.
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 162(10)
HIV entry is determined by one or more chemokine receptors. T cell-tropic viruses bind CXCR4, whereas macrophage-tropic viruses use CCR5 and other CCRs. Infection with CXCR4 and CCR5-tropic HIV requires initial binding to CD4, and chemotaxis induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::718747618f335716aff8ae1e174ce5b9
https://pubmed.ncbi.nlm.nih.gov/10229873
https://pubmed.ncbi.nlm.nih.gov/10229873
Autor:
D P, Francis, T, Gregory, M J, McElrath, R B, Belshe, G J, Gorse, S, Migasena, D, Kitayaporn, P, Pitisuttitham, T, Matthews, D H, Schwartz, P W, Berman
Publikováno v:
AIDS research and human retroviruses. 14
AIDSVAX (VaxGen, Inc., South San Francisco, CA), a possible vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection, is being tested for efficacy in phase 3 studies. It has been tested for potential efficacy in chimpanzees, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bb60ac11d22eadc9b6ca4b1be0f342c0
https://pubmed.ncbi.nlm.nih.gov/9814961
https://pubmed.ncbi.nlm.nih.gov/9814961
Autor:
B S, Graham, M J, McElrath, R I, Connor, D H, Schwartz, G J, Gorse, M C, Keefer, M J, Mulligan, T J, Matthews, S M, Wolinsky, D C, Montefiori, S H, Vermund, J S, Lambert, L, Corey, R B, Belshe, R, Dolin, P F, Wright, B T, Korber, M C, Wolff, P E, Fast
Publikováno v:
The Journal of infectious diseases. 177(2)
Among 2099 uninfected subjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human immunodeficiency virus type 1 (HIV-1) infection. High-risk sexual exposures accounted for 17 infections, and intravenous dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3eae35717f1a9d7e47373b99281b3523
https://pubmed.ncbi.nlm.nih.gov/9466516
https://pubmed.ncbi.nlm.nih.gov/9466516